Opinions on the stock are mixed, with 3 analysts rating it as a “buy”, 1 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for MAZE is 13.08M, and at present, short sellers hold a 16.40% of that float. On July 04, 2025, the average trading volume of MAZE was 153.18K shares.
MAZE stock’s latest price update
The stock price of Maze Therapeutics Inc (NASDAQ: MAZE) has plunged by -3.04% when compared to previous closing price of $11.86, but the company has seen a -9.73% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-29 that SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, today announced that Jason Coloma, Ph.D.
MAZE’s Market Performance
Maze Therapeutics Inc (MAZE) has experienced a -9.73% fall in stock performance for the past week, with a -15.81% drop in the past month, and a 10.90% rise in the past quarter. The volatility ratio for the week is 10.08%, and the volatility levels for the past 30 days are at 9.62% for MAZE. The simple moving average for the last 20 days is -5.91% for MAZE stock, with a simple moving average of 3.87% for the last 200 days.
MAZE Trading at 4.69% from the 50-Day Moving Average
After a stumble in the market that brought MAZE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.35% of loss for the given period.
Volatility was left at 9.62%, however, over the last 30 days, the volatility rate increased by 10.08%, as shares sank -17.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.63% upper at present.
During the last 5 trading sessions, MAZE fell by -9.73%, in comparison to the 20-day moving average, which settled at $12.22. In addition, Maze Therapeutics Inc saw N/A in overturn over a single year, with a tendency to cut further N/A.
Insider Trading
N/A, the N/A of Maze Therapeutics Inc, N/A N/A shares at N/A during a trade that took place back on N/A, which means that N/A is holding N/A shares at N/A based on the most recent closing price.
Stock Fundamentals for MAZE
Current profitability levels for the company are sitting at:
- -44.96% for the present operating margin
- 1.0% for the gross margin
The net margin for Maze Therapeutics Inc stands at -32.36%. The total capital return value is set at -0.36%.
Based on Maze Therapeutics Inc (MAZE), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -3.71.
Currently, EBITDA for the company is 60.88 million with net debt to EBITDA at 2.44. When we switch over and look at the enterprise to sales, we see a ratio of 94.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.10.
Conclusion
To sum up, Maze Therapeutics Inc (MAZE) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
